44 results about "Depression model" patented technology

The invention discloses application of traditional Chinese medicine monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the same) in preparation of drugs for treating nerve injury diseases and a preparation method of the drugs for treating the nerve injury diseases. The pharmacological action mechanism of the monomer poplar bud flavin is deeply explored, and animal model application effect verification proves that the monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the homologues) can obviously improve core symptoms of cerebral apoplexy, autism, Alzheimer's disease and depression models, is high in safety, and can be used for preparing a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression models. The invention also develops a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression, which takes the poplatin as a core component (including homologues of the poplatin and extracts / mixtures containing the poplatin), and is expected to provide new research results and application schemes for treatment of nerve injury diseases such as cerebral apoplexy, autism, Alzheimer's disease, depression and the like. The important significance is realized on improving the treatment effect.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention discloses application of 4-isopropyltoluene to improvement of depression-like behaviors of mice. An experiment adopts a chronic constraint stress method to construct a depression model, through behavioral detection such as a sucrose preference test, a tail suspension test and a novel inhibition ingestion test, and in combination with molecular biology means such as immunofluorescent staining and Western blot, the anti-depression effect and potential mechanism of 4-isopropyltoluene are systematically evaluated, and the anti-depression effect and potential mechanism of 4-isopropyltoluene are evaluated. Results show that 4-isopropyltoluene plays a significant anti-depression role by inhibiting neuroinflammation, enhancing glial cell support function and activating AKT signal pathway, and has the potential of being developed into a novel anti-depression candidate drug.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.

The invention relates to the technical field of biomedicine, in particular to an ELS-induced depression-like behavior rat whole-brain tissue lipid space metabolism analysis method which comprises the following steps: firstly, constructing an ELS-induced depression-like behavior rat model, and determining a depression model group by adopting a depression-like behavior test; then, taking a conventionally fed rat as a control group, respectively carrying out 2D scanning on the control group and the depression model group based on a mass spectrum space omics technology, constructing a 2D brain lipid map, and carrying out whole-brain 3D reconstruction to obtain brain tissue lipid mass spectrum imaging data; and finally, carrying out metabolic heterogeneity analysis on brain tissue lipid mass spectrum imaging data. The method provided by the invention aims to provide technical and data atlas support for research on a lipid metabolism disorder molecular mechanism of occurrence and development of early-stage negative stress induced depression from an animal model level, and meanwhile, the application range of a mass spectrum space omics technology is expanded.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The invention provides a text-based gait depression detection method and device, equipment and a medium, and effectively solves the problem of low accuracy of an existing gait depression detection mode. The method comprises the following steps: extracting sample gait silhouette features from multiple frames of obtained sample gait silhouette images, and fusing the sample gait silhouette features and sample general text features to obtain sample gait text features; collecting sample scales with personalized answers replied by the plurality of sample detection objects to extract sample personalized text features; constructing an initial depression model based on the sample gait text features, and guiding the training of the initial depression model through the sample individual text features to obtain a depression model; and acquiring multiple frames of to-be-detected gait silhouette images of a target detection object during gait walking, and detecting the multiple frames of to-be-detected gait silhouette images based on the depression model to obtain a depression detection result of the target detection object.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The invention relates to the technical field of medicines, and particularly provides application of a 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound derivative in preparation of an antidepressant drug. A cell experiment proves that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound is an antagonist of an adenosine 2A receptor, and a plurality of animal model experiments prove that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound has a relatively good treatment effect on a plurality of depression models. The compound has an application prospect of being used as an anti-depression treatment drug.

The invention provides a lipidosome preparation capable of performing brain-targeted drug delivery in a depression model, a preparation method of the lipidosome preparation and application of the lipidosome preparation in improving the anti-depression effect of fluoxetine, and belongs to the technical field of pharmaceutical preparations. The composition disclosed by the invention consists of DOPG, DSPE-PEG2000-PGP, DSPE-PEG2000, cholesterol, fluoxetine and celecoxib, and can be used for improving the anti-depression effect of fluoxetine. The double-drug-loading liposome with high entrapment efficiency and uniform particle size is prepared through a film hydration-film extrusion method, has good stability and biocompatibility, has an obvious targeting drug delivery effect in a chronic social contusion stress model, is suitable for a combined treatment strategy of depression, and has a good clinical application prospect.

The invention discloses a multi-wavelength laser mode adaptive switching method and system for a depression model, and relates to the technical field of laser adaptive switching. The multi-wavelength laser mode adaptive switching method and system for the depression model comprises the following steps: S1, constructing a multi-source stimulation data set, and performing quality marking and normalization processing; s2, constructing an equipment channel characteristic parameter set, and performing online correction and stability evaluation; s3, generating an equipment compensation stimulation sequence, and performing multi-wavelength laser mode adaptive switching and compensation; and S4, carrying out multi-source stimulation data full-link association and blood relationship management. According to the invention, the consistency of multi-wavelength laser stimulation output among multiple devices and the repeatability of depression model experiment conditions are effectively improved, and the problem that the physical output of the same stimulation scheme on different experiment devices is inconsistent is solved.

The invention discloses a homogeneous polysaccharide from Xiaoyao powder as well as a preparation method and application of the homogeneous polysaccharide. The homogeneous polysaccharide is composed of arabinose, galactose, mannose, glucose and fructose, and the weight-average molecular weight Mw of the homogeneous polysaccharide is 293.223 kDa. The polysaccharide is separated and purified from Xiaoyao powder through water extraction, alcohol precipitation, ion exchange column chromatography, gel column chromatography and other preparation methods. Experimental results show that the homogeneous polysaccharide can improve cortisol-induced zebra fish depression model behavioral performance and improve exercise activity, has anti-depression activity, and can be used for preparing drugs for treating or preventing depression.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The invention provides application of Turicibacter sanguinis in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. Researches find that compared with depression model mice, mice treated by T. sanguinis show significant behavior improvement: sucrose consumption is increased, retention time in an interaction area in a social interaction experiment (a CD1 mouse introduction stage) is prolonged, retention time and total movement distance in a central area in an open field experiment are both increased, and the mice treated by T. sanguinis show significant behavior improvement. And meanwhile, the standing time in a forced swimming experiment is shortened. The results of the behavioral test are consistent to show that the depression-like behavior of the mouse can be obviously alleviated by the T. sanguinis intervention.

The invention relates to the technical field of medicines, in particular to a composition for relieving depression, a preparation and application of the composition. The composition for relieving depression is prepared from the following components in parts by weight: 1 to 3 parts of nicotine and 100 to 5000 parts of imipramine. On a constructed mouse chronic unpredictable stress depression (CUMS) model, depression-like behavioral characteristics of model animals can be remarkably improved by intraperitoneal injection of low dose of nicotine and different doses of imipramine, and the effect is superior to that of a group singly using nicotine and a group singly using imipramine; the effect of rapidly relieving depression-like symptoms of animals can be achieved through the cooperation of low-dose nicotine and imipramine.

The invention relates to the technical field of medicines, in particular to application of artemisia vulgaris in preparation of an anti-depression medicine. According to the application disclosed by the invention, the depression is systematically researched through a chronic depression model induced by chronic unpredictable mild stress (CUMS) and an acute depression model induced by lipopolysaccharide (LPS). Experimental results show that under the stimulation of CUMS or LPS, experimental animals show obvious depression-like behaviors. Compared with a negative control group, depression-like behaviors of mice in the CUMS model group and the LPS model group are confirmed, and behavior abnormalities induced by the two models can be effectively improved after intervention of the artemisinin. Further comparative research finds that the antidepressant effect of the clinically common antidepressant drug venlafaxine with the dosage of 10 mg / kg can be achieved under the dosage of 1 mg / kg of the artemisinin, and the artemisinin has remarkable antidepressant activity. The application has a good application prospect when being applied to the development of anti-depression drugs.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

The invention discloses application of allyl isothiocyanate in preparation of drugs or health-care foods for improving mental disorder, and belongs to the technical field of medicines. Allyl isothiocyanate shows rapid, convenient and efficient intervention potential for depression, emotional disorder, social difficulty, biphasic emotional fluctuation, anxiety and autism spectrum symptoms when used as a functional component of a medicine or health food. Specific experiments verify that in a depression model constructed by adopting social contusion stress, the component can obviously reverse typical depression-like behaviors such as social avoidance tendency and behavioral despair states shown by mice. In a chronic unpredictable stress induced model, allyl isothiocyanate effectively relieves anxiety and depression symptoms of mice and recovers pleasant sensation experience ability of the mice. In a drug-induced bipolar affective disorder model, the component obviously stabilizes the manic attack and depression alternating behavior of mice. In an autism model mouse, the allyl isothiocyanate effectively relieves the repetitive engraving behavior of the autism model mouse.

The invention relates to application of 4 '-demethyl epipodophyllotoxin or a medicinal derivative thereof in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious nervous and mental disease and affects millions of people in the world. Major depression is the most common mental disorder and is also one of the main causes of global disability. Depression is considered to be a complex disease caused by interaction of genetic, physiological, psychological and environmental factors. It is found that the novel antidepressant drug capable of treating depression has great significance. A per2- / -mutant zebrafish depression model is utilized to perform drug screening on traditional Chinese medicine monomers, and finally, 10 mu M of 4 '-demethylepipodophyllotoxin has an anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish. A medicinal plant podophyllotoxin from which 4 '-demethyl epipodophyllotoxin is extracted is safe and non-toxic, and no report about 4'-demethyl epipodophyllotoxin depression resistance exists at present.

The invention discloses lactobacillus reuteri FMZ07 and application thereof in depression resistance and intestinal flora improvement, and belongs to the technical field of biomedicine. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC for short), the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.37751, the preservation date is February 9, 2026, and the strain is named as Lactobacillus reuteri in taxonomy. The strain can regulate'microorganism-intestine-brain axis' through multiple targets, the depression-like behavior of depression model mice is remarkably improved, meanwhile, the richness and uniformity of intestinal flora are recovered, and reliable microorganism resources are provided for developing probiotic preparations or drugs for improving depression and assisting improvement of intestinal flora.

The invention belongs to the technical field of biological medicine, and particularly discloses application of secoxyloganin in preparation of an antidepressant drug, and the antidepressant drug further contains a pharmaceutically acceptable carrier. The antidepressant drug is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspending agent, an emulsion, a solution, powder, tablets, granules and capsules. When the secoxyloganin is used as the effective component of the antidepressant drug, the depression-like behavior of a depression model mouse induced by LPS (Lipopolysaccharide) can be effectively improved.

This invention discloses the use of silybin derivatives or their stereoisomers, or pharmaceutically acceptable salts, with the structure shown in Formula I in the preparation of medicaments for the prevention and / or treatment of depressive disorders; R1, R2, R3, R4, R5, and R6 are independently selected from hydrogen, methyl, and methyl groups. Compared with silybin alone, royal jelly acid, or a combination of silybin and royal jelly acid, the silybin derivatives of this invention exhibit more significant effects on mouse models of depression induced by chronic social frustration stress and chronic restraint stress, even with significantly reduced dosage, and can be used to prepare medicaments for the treatment of depressive disorders.

The invention belongs to the technical field of disease animal model construction, and particularly relates to a construction method and application of a CUMS depression model based on bee behavioristics, and the construction method comprises the following steps: carrying out adaptive culture on bees for 22-26 hours, and then carrying out stress treatment for 8 days; a stress source for stress treatment is oscillation treatment, hunger treatment, isoamyl acetate odor treatment and electric shock treatment; during stress treatment, each stress source is given for two days in a random mode, and the same stimulation cannot be accepted for two continuous days. According to the method, the CUMS depression model is constructed by taking bees as research objects, and compared with zebra fish, the bees as social insects have social structures similar to those of human beings and can simulate some behaviors and phenomena in the human society; compared with primates and rodents, the bees are lower in breeding cost and high in breeding speed, and compared with the primates, the bees are used as experimental animals, and the dispute in ethics is relatively small.

The invention discloses an adjustable binding and fixing device for a mouse depression model, and relates to the technical field of experimental animals. Comprising a containing pipe, a conical head is arranged at one end of the containing pipe, a plurality of ventilation holes are formed in the conical head, a longitudinal opening is formed in the pipe wall of the containing pipe, one end of the longitudinal opening extends to the end, away from the conical head, of the containing pipe, and the other end of the longitudinal opening extends to one side of the conical head; the inner diameter of the adjustable restraining piece is matched with the outer diameter of the containing pipe, the adjustable restraining piece is detachably installed on the outer side of the containing pipe, the adjustable restraining piece is of a C-shaped structure, connecting pieces are integrally arranged at the two ends of the adjustable restraining piece, and adjusting parts are arranged on the connecting pieces. Through the cooperative design of the C-shaped adjustable restraining piece and the adjusting screw, continuous adjustment of the inner diameter of the containing pipe is achieved, the device is suitable for laboratory mice of different body types, precise adaptation of the mouse body types is achieved, and restraining effectiveness and safety are ensured.

The utility model provides a rat depression behavior observation device which comprises a box body, a plurality of supporting legs are arranged at the bottom of the box body, a box cover is hinged to the top of the box body, and the interior of the box body is divided into a drying area and a cold water experiment area through a partition plate. A semiconductor refrigerator penetrates through the bottom of the box body corresponding to the cold water experiment area, and a pedal penetrates through the side wall of the box body corresponding to the cold water experiment area in a sliding manner; the drying area is provided with an electric push rod. The telescopic end of the electric push rod is provided with an extrusion plate. The lower part of the box cover is provided with infrared cameras corresponding to the drying area and the cold water experiment area, and the bottom of the box body is provided with a water outlet corresponding to the cold water experiment area. According to the rat depression behavior observation device, forced swimming experiments can be conveniently carried out on rats in cold water with different temperatures, irradiation with different illumination intensities can be conveniently carried out on the rats, rat depression models can be manufactured in multiple modes, depression behaviors of the rats in a dark environment can be conveniently observed, and the rat depression behavior observation device is convenient to use. The structural design is ingenious, and functions are rich.

The application discloses application of hippuric acid in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. The hippuric acid or pharmaceutically acceptable salt thereof has significant and multi-target antidepressant pharmacological activity through chronic mild stress depression animal model experiment. Specifically, in terms of improving core depressive symptoms, the sugar water preference experiment result shows that the hippuric acid can effectively reverse CUMS-induced hedonic deficiency of mice, and significantly improves the sucrose preference rate, and the forced swimming experiment proves that the hippuric acid can significantly shorten the immobility time of mice and relieve behavioral despair; in terms of improving anxiety-like behavior, the mine field experiment data show that after the hippuric acid intervention, the number of times of entering the central area, the residence time and the total activity distance of the depressive model mice are all significantly increased, which indicates that the hippuric acid can effectively improve the spontaneous activity reduction caused by chronic stress.

The invention relates to a method for high-throughput screening of antidepressant drugs and application of pectolinarin in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious neurological and mental disease and affects millions of people in the world. Major depression is one of common mental diseases and is also one of main reasons causing global disability. It is found that the new antidepressant drug capable of treating depression has important significance. According to the application, firstly, an animal model, namely, a per2- / -mutant zebrafish depression model, capable of realizing high-throughput screening of antidepressant drugs is constructed, secondly, the model is used for drug screening of traditional Chinese medicine monomers, and finally, it is found that 10 mu M of pectolinarin can effectively rescue depression-like phenotypes of per2- / -mutant zebrafish. A new strategy is provided for precise treatment of depression, a potential pharmacological mechanism of depression is researched, and an effective means is expected to be provided for clinical treatment of depression.

The application discloses a composition for treating depression and application thereof, and the composition for treating depression comprises the following components in parts by weight: ligustilide 35-40 parts, arturn 0.5-1.5 parts and alpha-cyperone 0.1-1 part; the application firstly compounding active ingredients in Yujia pills which target 5-HT1AR and 5-HTT, and preparing a new traditional Chinese medicine efficacy component composition; in addition, the anti-depression efficacy of the active ingredients is evaluated by establishing a reserpine mouse depression model, and it is shown that the active ingredient composition screened from the 5-HT1AR and 5-HTT targets can regulate the content of monamine neurotransmitters in brain tissues to exert the anti-depression efficacy, and the in-vivo pharmacological experiment fully proves the anti-depression efficacy of the composition.

The application relates to the field of biomedical technology, in particular to a method for analyzing lipid spatial metabolism of whole brain tissue of ELS-induced depression-like behavior rats, which comprises the following steps: first, an ELS-induced depression-like behavior rat model is constructed, and a depression model group is determined by adopting a depression-like behavior test; then, a conventional rat is taken as a control group, 2D scanning is carried out on the control group and the depression model group based on mass spectrometry spatial omics technology, 2D brain lipid maps are constructed, and whole brain 3D reconstruction is carried out to obtain brain tissue lipid mass spectrometry imaging data; finally, metabolic heterogeneity analysis is carried out on the brain tissue lipid mass spectrometry imaging data. The method provided by the application aims to provide technical and data atlas support for the research on the molecular mechanism of lipid metabolism disorder in the occurrence and development of early negative stress-induced depression from the animal model level, and simultaneously expands the application range of mass spectrometry spatial omics technology.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.